Promacta and Jakavi May Boost Novartis’s Oncology Segment Revenues
Novartis: What Are the Major Growth Drivers for 2018? Novartis’s (NVS) Promacta reported sales if $255 million in 4Q17, which is a year-over-year (or YoY) rise of 43.0% on a constant currency basis. On January 4, 2018, Novartis announced that the FDA granted breakthrough therapy designation to the combination of Promacta and immunosuppressive therapy.